|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that the supernatant from IFN-<i>α</i>-treated cultured cells restricted HBV and HCV infection by inhibiting viral entry into hepatoma cells.
|
28367455 |
2017 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conducted an open-label trial to assess the efficacy and safety of sofosbuvir (SOF) plus pegylated interferon (Peg-IFN) and ribavirin (RBV) in patients with genotype 1 hepatitis C virus (HCV) who participated in previous studies of one or more Gilead investigational DAAs in combination with RBV with or without Peg-IFN.We enrolled 80 patients at 40 sites.
|
25847509 |
2015 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a randomized, controlled trial to test the efficacy and safety of pretransplant pegylated interferon alpha-2b plus ribavirin (Peg-IFN-α2b/RBV) for prevention of post-transplant HCV recurrence.
|
22821361 |
2013 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conducted a cohort study of HIV/HCV-coinfected women followed in the multicentre, NIH-funded Women's Interagency HIV Study (WIHS) to investigate whether 10 polymorphisms spanning the IFN-λ region were associated with liver-related mortality by dominant, recessive or additive genetic models.
|
26115445 |
2015 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that BCL-2 gene polymorphism at codon 43 (127G/A) is a new biological marker to potentially identify responders and non-responders of HCV genotype 4 patients to achieving a sustained virological response to treatment with IFN in combination with ribavirin.
|
21159314 |
2011 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We compared IFNL4-ΔG/TT and rs4803217 for association with response to pegylated-IFN-α/ribavirin in the VIRAHEP-C and HALT-C trials, and spontaneous HCV clearance in the ALIVE, UHS and WIHS studies.
|
26186989 |
2015 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also plan to identify patient characteristics that contribute to the development of PEG-IFN α-2a-induced neutropenia in hepatitis C patients.
|
29872876 |
2018 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vitamin D supplementation in combination with Peg-IFN-α injection and oral RBV significantly increased the rate of viral response for hepatitis C at 24 weeks after treatment in a random-effects meta-analysis (relative risk = 1.30; 95% confidence interval = 1.04-1.62; I<sup>2</sup> = 75.9%).
|
28833855 |
2018 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Variations in rs14158 are associated with SVR to Peg-IFN and RBV in HIV/HCV-coinfected patients harboring HCV genotype 1-4.
|
21572301 |
2011 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Variants of rs2111485 and rs1990760 at <i>IFIH1</i> may be associated with spontaneous HCV clearance in Chinese Han population, but have no effect on HCV clearance induced by IFN-<i>α</i>.
|
31539314 |
2019 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using the HCV replicon system and cell culture infectious reporter virus, we compared IFN-alpha and IFN-lambda effects on HCV RNA replication and protein expression, as measured by quantitative reverse-transcriptase polymerase chain reaction, luciferase expression, and Western blot.
|
17087946 |
2006 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using an enzyme-linked immunosorbent assay, we assessed the prevalence of anti-ARF/core+1 antibodies in 90 chronic hepatitis C patients infected with HCV genotypes 1a/1b or 3a, treated with pegylated interferon (Peg-IFN-a-2a) plus ribavirin.
|
22329372 |
2012 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Until recently, chronic hepatitis C caused by persistent infection with the hepatitis C virus (HCV) has been treated with a combination of pegylated interferon-alpha (PEG-IFNα) and ribavirin (RBV).
|
22212566 |
2012 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.
|
23627926 |
2013 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Under the conditions of impaired lipid β-oxidation, host cells were less responsive to the ability of exogenously added IFN-α to suppress HCV replication.
|
25673715 |
2015 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two large clinical trials determined that each PEG-IFN alfa compound, when given in combination with ribavirin, results in overall sustained virological response (SVR) rates of approximately 50%; SVR rates in patients infected with hepatitis C virus (HCV) genotype 1 are typically lower (42-46%).
|
18363672 |
2008 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two hundred HCV responders to pegylated IFN-α-2a plus ribavirin were selected.
|
28873034 |
2017 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty-eight patients infected with HCV-4 were given peg-IFN plus ribavirin for 48 weeks.
|
16032749 |
2005 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Twenty hepatitis C virus (HCV) genotype 1 patients with high viral load and Metavir fibrosis score >or=2 without HIV co-infection who were previously nonviral responders to standard treatment with IFN plus ribavirin were intensively re-treated with IFN-alpha2a (3 millions (M) IU every 2 days) combined with ribavirin (1000-1200 mg/day) for a 24-week period.
|
16436132 |
2006 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twelve patients who responded to IFN therapy with clearance of HCV showed an increase of the platelet count, whereas the 10 patients who did not respond to IFN showed a decrease of the platelet count.
|
16191092 |
2005 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Triple therapy using telaprevir or boceprevir [hepatitis C virus (HCV)-NS3/NS4A protease inhibitors (PI)] in association with PEG-IFN/ribavirin has recently become the new standard of care (SOC) for treatment of HCV genotype 1 patients.
|
24612466 |
2014 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Triple therapy for 12 weeks, followed by PEG-IFN and RBV for 12 weeks, was given to 49 patients with RBV-sensitive (CC at rs1127354) and 12 with RBV-resistant (CA/AA) ITPA genotypes who had been infected with hepatitis C virus (HCV) of genotype 1.
|
21246582 |
2011 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment-emergent depression is a common complication in patients with chronic hepatitis C virus (HCV) infection undergoing antiviral combination therapy with IFN-α and ribavirin.
|
31332697 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with mericitabine plus Peg-IFNα-2a/RBV for 8 or 12 weeks provided potent suppression of HCV RNA, was well tolerated, and did not select resistant variants, but did not increase SVR rates, compared to placebo.
|
23348636 |
2013 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment and retreatment with IFN was associated in our non-responder patients with evolution of the ISDR quasispecies towards a rather homogeneous viral population carrying a conserved or minimally mutated ISDR motif, supporting the idea that this motif may be relevant for IFN resistance in HCV 1b-infected individuals.
|
10607252 |
1999 |